ライフサイエンスコーパス: immunomodulator

1 apse 24 months after they stopped taking the immunomodulator).

2 mes at 1 year than early monotherapy with an immunomodulator.

3 growing evidence that vitamin D is a potent immunomodulator.

4 ltoheptaose was identified from WG-PS3 as an immunomodulator.

5 a previously unknown function for GP2 as an immunomodulator.

6 f estrogen, a well-known neuroprotectant and immunomodulator.

7 to function as both a primary adhesin and an immunomodulator.

8 -TNF agent and 2676 patients treated with an immunomodulator.

9 ro- and anti-inflammatory properties of this immunomodulator.

10 vealing a potential function of VEGF-C as an immunomodulator.

11 unconventional amino acid ethionine, a known immunomodulator.

12 entified human anti-microbial metabolite and immunomodulator.

13 and is under investigation as a non-specific immunomodulator.

14 new targets for intervention, as well as new immunomodulators.

15 ancer cells and provide sustained release of immunomodulators.

16 new targets for intervention, as well as new immunomodulators.

17 atory destruction in vitro and are promising immunomodulators.

18 iculate vaccines, drug delivery systems, and immunomodulators.

19 s that of a physical linkage between Ags and immunomodulators.

20 mulation from other allergens or copresented immunomodulators.

21 es (such as ATP and UTP) have emerged as key immunomodulators.

22 therapeutically delivering nucleic acids as immunomodulators.

23 could result in more effective vaccines and immunomodulators.

24 to the conserved structural features of HCMV immunomodulators.

25 tentially be developed into orally available immunomodulators.

26 the potential interference of tumor-derived immunomodulators.

27 and may have clinical utility as stand-alone immunomodulators.

28 e receiving BM185 cells expressing all three immunomodulators.

29 ity triggered by systemic delivery of potent immunomodulators.

30 gn and their biological applications such as immunomodulators.

31 plications for the use of CpG-A and CpG-B as immunomodulators.

32 SCs) have been studied for decades as potent immunomodulators.

33 ogic monotherapy vs combination therapy with immunomodulators, (3) comparative efficacy of top-down (

34 lpha was superior to early treatment with an immunomodulator (85.3% vs 60.3% in remission; relative r

35 Therefore, development of adjuvants and immunomodulators able to enhance cell-mediated immune re

36 the evaluation of the antitumor efficacy of immunomodulator Abs in syngeneic models.

37 .05 [95% confidence interval, 1.07-3.93] and immunomodulator adjusted odds ratio, 1.81 [95% confidenc

38 imply as an immunosuppressant, but as a mild immunomodulator, administration of glucosamine provides

39 subcutaneous administration of this defined immunomodulator affords protection against joint disease

40 nts with Crohn's disease who discontinued an immunomodulator after combination therapy found that rat

41 isease (CD) includes early administration of immunomodulators after initial treatment with corticoste

42 f curdlan, a naturally occurring beta-glucan immunomodulator, against visceral leishmaniasis, a fatal

43 ode activation, and skin sensitization using immunomodulators agonistic for a family of sphingosine-1

44 ainst divergent strains, act as adjuvants or immunomodulators, allow for sustained release of antigen

45 74 (19%) of 400 were escalated to immunomodulators alone, 123 (31%) anti-TNFalpha therapy,

46 Future investigation of the effects of immunomodulators among transplant recipients with COVID-

47 will enhance the potency of sunitinib as an immunomodulator and a cancer therapy.

48 al attention as both a Th1-like inflammatory immunomodulator and a pathogenic co-stimulator of autore

49 These results demonstrate that ARID2 is an immunomodulator and a potential biomarker that indicates

50 tor that is being investigated as a targeted immunomodulator and disease-modifying therapy for rheuma

51 P [c-diguanylate]) is a novel small molecule immunomodulator and immunostimulatory agent that trigger

52 Vitamin D is a strong immunomodulator and may protect against adverse pregnanc

53 factor (MIF) has been characterized as a key immunomodulator and mediator of various diseases.

54 in C57BL/6 mice since estrogen is a natural immunomodulator and we have recently reported that estro

55 erate to severe UC often requires the use of immunomodulator and/or biologic therapies, including thi

56 nosalicylates in patients being treated with immunomodulator and/or biologic therapy for moderate to

57 these common sublethal infections may act as immunomodulators and affect population dynamics through

58 orption diseases and are also of interest as immunomodulators and anti-infectives.

59 tionally, antiepileptic maneuvers may act as immunomodulators and anti-inflammatory therapies can tre

60 Postoperative immunomodulators and antitumor necrosis factor agents ma

61 d progress to more potent treatments such as immunomodulators and biologic agents.

62 l disease (IBD) is increasingly managed with immunomodulators and biologic agents.

63 r KPro use but studies investigating various immunomodulators and biologic materials for improved ret

64 hysiology of severe asthma so more effective immunomodulators and biologic therapies can emerge.

65 Immunomodulators and biologics are now the preferred tre

66 The mainstays of treatment are immunomodulators and biologics, particularly anti-tumor

67 Parasitic helminths are potent immunomodulators and chronic infections may protect agai

68 ors (SCINs) are one important class of these immunomodulators and consist of three active members (SC

69 There have been reappraisals of immunomodulators and further evaluation of (yes, now con

70 Our data demonstrate that fungi are potent immunomodulators and have powerful effects on asthma ind

71 opment of small molecules targeting VISTA as immunomodulators and imaging probes.

72 -infectives and both microbe- and host-based immunomodulators and their feasibility for use in asthma

73 ions and have implications for the design of immunomodulators and vaccines containing beta-glucans.

74 t approaches favor the early introduction of immunomodulators and/or antitumor necrosis factor (TNF)

75 Most patients were treated with immunomodulators and/or immunosuppressive agents, result

76 aminosalicylates, 0.5 (95% CI, 0.3-0.9) for immunomodulators, and 0.8 (95% CI, 0.6-1.1) for corticos

77 (95% CI, 0.5-1.1), 1.3 (95% CI, 0.9-1.9) for immunomodulators, and 1.0 (95% CI, 0.7-1.4) for corticos

78 tion therapy, intratumoural therapies, other immunomodulators, and adaptive cell therapy, including c

79 d use of medications, particularly steroids, immunomodulators, and biological agents; and a high risk

80 secrete an extensive arsenal of hemolysins, immunomodulators, and exoenzymes to cause disease.

81 Male sex, treatment with immunomodulators, and leukopenia also influenced the ris

82 ysis included sex, ethnicity, treatment with immunomodulators, and leukopenia.

83 steroids, 5-aminosalicylic acid derivatives, immunomodulators, and more recently thalidomide and pent

84 afety of long-term therapy with anti-TNF and immunomodulators, and predictors of relapse following th

85 y or autoimmune disorders), use of potential immunomodulators, and recent use of antibiotics or probi

86 Therapeutics including antivirals, immunomodulators, and vaccines are in development.

87 tional development of novel anti-infectives, immunomodulators, and vaccines.

88 ties of mesalamine, antibiotics, budesonide, immunomodulators, anti-tumor necrosis factor alpha (anti

89 Accelerated paths for antivirals, immunomodulators, anticoagulants, and other agents have

90 ior; beta-lactam antibiotics can function as immunomodulators, apparently through covalent binding to

91 rophylactic treatment with H. pylori-derived immunomodulators appears to be a promising strategy for

92 Teriflunomide is a once-daily oral immunomodulator approved for the treatment of relapsing-

93 Imiquimod, another topical immunomodulator, approved for genital wart treatment in

94 Presently low-dose steroids or immunomodulators are being used but efficacy of these me

95 Immunomodulators are effective in controlling hematologi

96 ty of the NF-kappaB response to a variety of immunomodulators are mediated by core circadian protein

97 I IFNs and ICSBP, and demonstrate that these immunomodulators are required for the immunoprotective e

98 reduced myeloid-derived suppressor cells and immunomodulators ARG1, CTLA-4, IL-6, IL-10, LAG3, and PD

99 In this study, we show that the helminth immunomodulator AvCystatin, a cysteine protease inhibito

100 The 'step-up' approach includes the use of immunomodulators [azathioprine (AZA), or 6-mercaptopurin

101 Using the immunomodulator B7-DC XAb to activate cytolytic T cells

102 FTY720, a potent immunomodulator, becomes phosphorylated in vivo (FTY-P)

103 s or older with a lower use of biologics and immunomodulators but higher absolute risk of bowel surge

104 D, elderly patients used fewer biologics and immunomodulators but more systemic corticosteroids.

105 uch as interleukins, chemotherapy, and other immunomodulators, but these adjuvant treatments are ofte

106 how one molecule can serve as a double-edged immunomodulator by directing discrete biological consequ

107 r results suggested that HCV NS5A acts as an immunomodulator by inhibiting IFN-gamma production and m

108 nal domain (BET) chromatin adaptors serve as immunomodulators by directly regulating Th17 responses a

109 Immunomodulators can be divided into those that are spec

110 Blood CD14(+) monocytes are frontline immunomodulators categorized into classical, intermediat

111 mune responses by introducing genes encoding immunomodulators (CD40 ligand (CD40L), CD80, and GM-CSF)

112 ding combination therapy with a biologic and immunomodulator compared to biologic monotherapy.

113 after treatment (19% after TNF and 17% after immunomodulators) compared with fit patients (9% after T

114 tly since the introduction of infliximab, an immunomodulator considered particularly effective in tre

115 have revealed that osteopontin, an important immunomodulator, contributes to the increased amounts of

116 As an oncoprotein as well as a potential immunomodulator, controlling SHP2 activity is of high th

117 cer-related diseases, as well as a potential immunomodulator, controlling SHP2 activity is of signifi

118 ibiting CD28 costimulation with the approved immunomodulator CTLA4Ig suppressed primary responses in

119 specificities, differ in sensitivity to the immunomodulator cyclosporin A.

120 uction] of immunomodulator monotherapy, 8 on immunomodulator de-escalation from combination therapy,

121 FTY720, a novel immunomodulator, displays potent immunosuppressive activ

122 FTY720 is a potent immunomodulator drug that inhibits the egress of lymphoc

123 the mycobacterial cell wall, and are potent immunomodulators during infection.

124 of medical therapy with aminosalicylates and immunomodulators during pregnancy.

125 both viruses induced a transient increase in immunomodulators, followed by viral clearance.

126 ds to be considered in evaluating IL-7 as an immunomodulator for HIV-infected patients.

127 zMPC, a novel probiotic product, is a potent immunomodulator for macrophages and may be beneficial fo

128 -tumor necrosis factor (TNF) agent and/or an immunomodulator for patients with inflammatory bowel dis

129 leukin-7 (IL-7) is a prospective therapeutic immunomodulator for the treatment of HIV, we evaluated t

130 ficial; here, we discovered that FTY-720, an immunomodulator for treating multiple sclerosis, can rev

131 e available in recent years, such as topical immunomodulators for atopic dermatitis, leukotriene anta

132 ory in current clinical trials using several immunomodulators for boosting antiviral immunity, immuno

133 immunity and for their development as novel immunomodulators for clinical use.

134 a single agent and in combination with other immunomodulators for inhibition of T-cell proliferation

135 e of ribavirin (alone or in combination with immunomodulators) for the treatment of respiratory syncy

136 igated the therapeutic efficacy of the novel immunomodulator FTY720 (Fingolimod), alone and in combin

137 The immunomodulator FTY720 (FTY) has been shown to be benefi

138 The novel immunomodulator FTY720 down-modulates sphingosine-1-phos

139 Administration of the immunomodulator FTY720 increased serum S1P, improved imp

140 receiving BM185 cells expressing two or more immunomodulator genes rejected challenge 50-76% of the t

141 We have reported that an immunomodulator, glucan phosphate, induces protection in

142 However, to date only a few immunomodulators have been evaluated for their efficacy

143 vents of potent treatment with biologics and immunomodulators have been recognized.

144 Osteopontin (OPN) is an immunomodulator highly expressed in dystrophic muscles.

145 95% CI, 1.37-2.22) or in combination with an immunomodulator (HR, 2.01; 95% CI, 1.57-2.58).

146 ferent medication regimens: (1) conventional immunomodulators (ie, oral prednisolone >10 mg/day, thio

147 h pre-established criteria for escalation to immunomodulators (ie, thiopurines) or anti-tumor necrosi

148 Besides acting as an immunomodulator, IFN-alpha elicits a pleiotropic antivir

149 vel chemotherapies including epothilones and immunomodulators (IMiDs), as well as other novel agents

150 lymerase inhibitors in only 2 cases, and the immunomodulators imiquimod and thalidomide allowed 5 pat

151 i-GMP may be used clinically as an effective immunomodulator, immune enhancer, and vaccine adjuvant t

152 used clinically in humans and animals as an immunomodulator, immune enhancer, immunotherapeutic, imm

153 rial, CYT003, a Toll-like receptor-9 agonist immunomodulator, improved asthma control during inhaled

154 r necrosis factor (TNF)alpha with that of an immunomodulator in attaining clinical remission and faci

155 in, acting as an innate antibiotic and as an immunomodulator in diseases such as rosacea and psoriasi

156 t complement activation serves as a critical immunomodulator in lung cancer progression, acting to dr

157 Topical ophthalmic tofacitinib may act as an immunomodulator in patients with DED.

158 yl)ethyl]-1,3-propanediol hydrochloride), an immunomodulator in Phase III trials for patients with mu

159 the potential therapeutic use of this novel immunomodulator in the treatment of metastatic diseases.

160 propose a novel role for a HABP as an innate immunomodulator in the treatment of MSSA and MRSA surgic

161 stigate the potential of anti-infectives and immunomodulators in asthma.

162 DNAs) are currently being evaluated as novel immunomodulators in clinical trials.

163 have been studied for their potential use as immunomodulators in disease.

164 gh phosphocholine oligosaccharides are known immunomodulators in human nematode and trematode infecti

165 or dose reduction) of anti-TNF agents and/or immunomodulators in patients in remission from IBD.

166 d esters, have been used as highly effective immunomodulators in patients with multiple sclerosis and

167 go-related gene (ERG) potassium channels and immunomodulators in the control of rest and locomotor ac

168 ave been raised regarding the use of topical immunomodulators in young children with atopic dermatiti

169 imum tolerated dose of lenalidomide, an oral immunomodulator, in Japanese patients with relapsed adul

170 Clinical data using other immunomodulators, including 6-thioguanine, mycophenolate

171 Histamine is an important immunomodulator influencing both the innate and adaptive

172 Histamine is an important immunomodulator involved in allergic reactions and infla

173 choosing to stop either the anti-TNF or the immunomodulator is a case-by-case decision based on the

174 The importance of these immunomodulators is highlighted by the number of immune

175 onstrate that the oral administration of the immunomodulator JBT 3002 combined with i.p. injection of

176 ect of irinotecan (CPT-11) combined with the immunomodulator JBT 3002, a synthetic bacterial lipopept

177 at transcriptional regulation of a subset of immunomodulators, known as the staphylococcal superantig

178 The oral immunomodulator laquinimod did not reach the primary end

179 ory Takayasu arteritis have responded to the immunomodulator leflunomide.

180 include the proteasome inhibitor bortezomib, immunomodulator lenalidomide, and Bruton's tyrosine kina

181 mised their ability to induce NOD2-dependent immunomodulators like cyclooxygenase (COX)-2, suppressor

182 lobenzaprine; the analgesic nefopam; and the immunomodulator lobenzarit.

183 suggest that the use of costimulation-based immunomodulators may have significant repercussions on t

184 ests that high levels of vitamin D, a potent immunomodulator, may decrease the risk of multiple scler

185 ity Index (CCI), radiation and chemotherapy, immunomodulator medications, albumin, preoperative diagn

186 ctadecylammonium liposomes incorporating two immunomodulators (monomycolyl glycerol analog and polyin

187 antibiotics (RR, 0.41; 95% CrI, 0.15-0.92), immunomodulator monotherapy (RR, 0.33; 95% CrI, 0.13-0.6

188 antibiotics (RR, 0.26; 95% CrI, 0.08-0.61), immunomodulator monotherapy (RR, 0.36; 95% CrI, 0.17-0.6

189 Stopping immunomodulator monotherapy after a period of remission

190 lation [drug cessation or dose reduction] of immunomodulator monotherapy, 8 on immunomodulator de-esc

191 been used to promote the delivery of a model immunomodulator, mycophenolic acid (MPA), to the lymphat

192 erity (CDEIS) from the Study of Biologic and Immunomodulator Naive Patients in Crohn's Disease (SONIC

193 rom its role (i) as an immunogen, (ii) as an immunomodulator of host anti-inflammatory activities, or

194 We theorized that OMP P6 is a potent immunomodulator of human macrophages.

195 ing the possibility to use sGARP as a potent immunomodulator of inflammatory diseases including trans

196 st report to show the potential of VIP as an immunomodulator of Pg-stimulated inflammatory pathways i

197 Since the role of PGs as immunomodulators of human cerebral malaria (CM) has not

198 n be broadly applied to other small-molecule immunomodulators of interest for vaccines and immunother

199 athogenesis and high-throughput screening of immunomodulators of phagocytosis.

200 and provides evidence that EVs are required immunomodulators of the developing nervous system.

201 n) with anti-CD3 antibody (a T cell-directed immunomodulator) offers better protection than either en

202 e examined the effects of PGE2, a well-known immunomodulator, on the production of IL-23 by bone marr

203 chymal stromal cells (VmSCs) that are either immunomodulators or adipogenic.

204 ednisone at baseline, and no previous use of immunomodulators or biologics.

205 ated with early anti-TNFalpha therapy, early immunomodulator, or no early immunotherapy.

206 enable delivery of imaging contrast agents, immunomodulators, or chemotherapy agents in adoptive cel

207 our necrosis factor alpha (TNFalpha) agents, immunomodulators, or colectomy among those initially tre

208 interferon, pipobroman, anagrelide, approved immunomodulators, or no cytoreductive treatment).

209 ts, such as calcineurin inhibitors and other immunomodulators, or novel anti-inflammatory treatments,

210 interferon, pipobroman, anagrelide, approved immunomodulators, or observation without pharmacological

211 with fit patients (9% after TNF and 7% after immunomodulators; P < .01 for frail vs fit in both group

212 uct containing polyclonal antibodies, act as immunomodulator peripherally and centrally, and it can r

213 monoclonal antibodies, virulence disruptors, immunomodulators, phage therapies, microbiome-based ther

214 xamine the potency of two beta-chemokines as immunomodulators, plasmid DNA encoding beta-chemokines C

215 Sunitinib is also an immunomodulator, potently reversing myeloid-derived supp

216 Treatment with the three immunomodulators prevented or delayed mortality and weig

217 te dysregulation occurs through the negative immunomodulators programmed death-1 (PD-1) and suppresso

218 rgone a considerable and unique expansion of immunomodulator proteins, some of which we highlight as

219 pha, and downregulation of NF-kappa B by the immunomodulator pyrrolidinedithiocarbamate enhanced the

220 rotein or peptide antigens and a tolerogenic immunomodulator, rapamycin, to induce durable and antige

221 remained superior to early treatment with an immunomodulator (relative risk, 1.51; 95% CI, 1.20-1.89;

222 Consistent with this, ES-62, an immunomodulator secreted by the parasitic worm Acanthoch

223 Here, we employ ES-62, an immunomodulator secreted by tissue-dwelling Acanthocheil

224 design could be adapted to drive additional immunomodulators, sense other cancers, and potentially t

225 ents in clinical remission who are receiving immunomodulators should be assessed for mucosal healing

226 , controversies have emerged as to how these immunomodulators should be used in clinical practice, ei

227 H. pylori or treated with H. pylori-derived immunomodulators showed reduced anaphylaxis upon allerge

228 vaccination against a secreted tick salivary immunomodulator, sialostatin L2, can lead to decreased f

229 In the immunomodulator study, mice were treated with glucan pho

230 Immunomodulators such as Bacillus Calmette-Guerin and in

231 There is evidence that conventional immunomodulators such as mycophenolate mofetil and biolo

232 Immunomodulators such as SP-D and ST2 also contribute.

233 ammatory cell death that can be leveraged by immunomodulators such as the danger signal calreticulin.

234 Addition of immunomodulators such as thiopurines or possibly methotr

235 slation of several classes of small-molecule immunomodulators, such as imidazoquinoline TLR7/8 agonis

236 on of inflammatory cytokines and noncytokine immunomodulators, such as PGE2, during differentiation a

237 The topical immunomodulators tacrolimus and pimecrolimus have been e

238 treatment of skin disease, using the topical immunomodulators tacrolimus, pimecrolimus, and imiquimod

239 t shutoff (vhs) protein is a multifunctional immunomodulator that counteracts the innate immune respo

240 We propose LJM11 as an immunomodulator that drives an efficient and controlled

241 Adenosine is an endogenous immunomodulator that has been shown to exhibit anti-infl

242 TLR4 protein levels in mice treated with an immunomodulator that increases survival in polymicrobial

243 hmania-derived trimannose represents a novel immunomodulator that provides early type 1-skewed cytoki

244 sgammac expression is a naturally occurring immunomodulator that regulates gammac cytokine signaling

245 hosphate dehydrogenase inhibitors, and other immunomodulators that are being evaluated as adjunctive

246 Mycobacterial lipids are potent immunomodulators that contribute to the granulomatous re

247 Studies on emerging immunomodulators that dampen autoreactivity without affe

248 such as the administration of antigens with immunomodulators that mobilize and activate endogenous D

249 trated that the anthrax toxins are important immunomodulators that promote immune evasion of the bact

250 Hence, immunomodulators that promote T(CM) responses of the Th1

251 resents a new class of vaccine adjuvants and immunomodulators that stimulate NKT cells to secrete Th1

252 Co-administration of immunomodulator therapy and adalimumab was associated wi

253 antiviral therapy and of combined antiviral-immunomodulator therapy for influenza.

254 Immunomodulator therapy is effective for patients with C

255 -up therapy (acceleration to biologic and/or immunomodulator therapy only after failure of 5-aminosal

256 l [CI], 1.14-1.75; P = .0017), whereas early immunomodulator therapy was no different than no early i

257 95% CI, 1.20-1.89; P = .0004), whereas early immunomodulator therapy was no different than no early i

258 y associated with combination adalimumab and immunomodulator therapy with that of adalimumab monother

259 of top-down (upfront use of biologics and/or immunomodulator therapy) vs step-up therapy (acceleratio

260 on of an anti-tumor necrosis factor (TNF) or immunomodulator therapy, from 1996 through 2010.

261 use of corticosteroids, laser, surgery, and immunomodulator therapy.

262 Studying viral immunomodulators therefore expands not only our understa

263 ly, glycine has been shown to be a potential immunomodulator; therefore, the purpose of this study wa

264 Combination immunomodulator (thiopurine or methotrexate) therapy mit

265 al strategy is the use of chemotherapy as an immunomodulator to enhance the effect of cancer vaccines

266 during fungal infection, where it acts as an immunomodulator to promote fungal clearance and to regul

267 The addition of immunomodulators to anti-TNF therapies can optimize thei

268 mia cells with lentiviral vectors to express immunomodulators to elicit antileukemic immune responses

269 cy and pluripotency evolved in tick salivary immunomodulators to evade immune recognition by the host

270 Switching from injectable immunomodulators to fingolimod is associated with fewer

271 n secrete high levels of cytokines and other immunomodulators to mediate host defense and tissue infl

272 he basis of nanomaterials' ability to direct immunomodulators to tumours and lymphoid organs, to alte

273 ither as monotherapy or in combination (with immunomodulators), to mitigate these risks.

274 pical and systemic corticosteroids, systemic immunomodulators, topical and systemic retinoids, and la

275 Immunomodulator treatments, including the recently popul

276 , while a mosquito bite alone induced strong immunomodulators (tumor necrosis factor alpha [TNF-alpha

277 witching therapy to fingolimod or injectable immunomodulators up to 12 months after on-treatment clin

278 associated with long-term corticosteroid and immunomodulator use if topical medication is not suffici

279 ncentrations showed an independent effect of immunomodulator use on week 54 non-remission (odds ratio

280 with ulcerative colitis supported continued immunomodulator use.

281 e and pomalidomide are members of a class of immunomodulators used as anticancer agents.

282 . pylori components (bacterial lysate or the immunomodulator VacA) and subsequently subjected them to

283 erinatal exposure to H pylori extract or its immunomodulator vacuolating cytotoxin confers robust pro

284 Here we report the development of new immunomodulators via control of shape transition among R

285 human immunodeficiency virus type 1 (HIV-1) immunomodulator VPU, reduced steady-state levels of bone

286 A concurrent immunomodulator was required.

287 el host cell proteins downregulated by viral immunomodulators, we previously observed that K5, as wel

288 F therapy and 7% of patients who received an immunomodulator were frail in the 2 years before immunos

289 hage population induced by a single parasite immunomodulator, which protects against mucosal inflamma

290 oactive intestinal peptide (VIP) is a potent immunomodulator, whose role in PDC function is unknown.

291 diseases, establishing CD45 as an important immunomodulator with a significant influence on disease

292 FTY720 is a novel immunomodulator with a unique mechanism of action, i.e.

293 monotherapy (RR, 0.36; 95% CrI, 0.17-0.63), immunomodulator with antibiotics (RR, 0.11; 95% CrI, 0.0

294 monotherapy (RR, 0.33; 95% CrI, 0.13-0.68), immunomodulator with antibiotics (RR, 0.16; 95% CrI, 0.0

295 Methotrexate is an immunomodulator with effects on helper T-cell signaling

296 unexpected features of SA-4-1BBL as a novel immunomodulator with implications for cancer immunopreve

297 how for the first time that AICAR is a novel immunomodulator with promising beneficial effects for th

298 Some fatty acids (FAs) are potent immunomodulators with virucidal activity, and their prim

299 Use of anti-TNF agents, corticosteroids, and immunomodulators within 90 days of surgery was identifie

300 VB radiation induces sunburn and is a potent immunomodulator, yet longer-wavelength, lower-energy UVA